BioXcel Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Amount
BioXcel Therapeutics, Inc. (BTAI) reported Effective Income Tax Rate Reconciliation, Tax Credit, Amount of $1.87 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-28.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCredits · last filed 2025-03-28
- BioXcel Therapeutics, Inc. effective income tax rate reconciliation, tax credit, amount for fiscal 2024 was $1.87M, a 54.19% decline from fiscal 2023.
- BioXcel Therapeutics, Inc. effective income tax rate reconciliation, tax credit, amount for fiscal 2023 was $4.08M.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Amount 12 month |
|---|---|
| 2024-12-31 | $1.87M 10-K · filed 2025-03-28 |
| 2023-12-31 | $4.08M 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |